Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A recent market commentary asks whether Pfizer can re-create its breakout cholesterol drug success in a market increasingly dominated by GLP-1-based therapies, and whether its next long-acting weight-loss effort can overcome years of relative lag.
THE APEX TIMES
THE APEX TIMES
Pfizer (PFE) closed at $23.72, down 2.47% from the prior day, according to a market recap published by Yahoo Finance on July 6.
THE APEX TIMES
The U.S. approval expands the use of palbociclib, marketed as Ibrance, positioning it as a first-of-its-kind CDK4/6 inhibitor maintenance therapy after induction treatment in a specific subtype of advanced breast cancer.
THE APEX TIMES
A fresh U.S. Food and Drug Administration approval expands the label for Pfizer’s Ibrance in a breast cancer setting, while a separate market column frames Pfizer’s dividend appeal as a reason hedge funds favor the stock.
THE APEX TIMES
In remarks highlighted by market coverage, Pfizer indicated it is looking at deal-making capacity, even as investors focus on the scale of the turnaround still ahead.
THE APEX TIMES
A market commentary framed Pfizer and Verizon Communications as two “high-yield” dividend plays, positioning both as established companies with fundamentals the author views as supportive. The available text does not include the underlying dividend or valuation figures that would normally be central to the debate.
THE APEX TIMES
A fresh market commentary argues that Pfizer’s stock (PFE) looks inexpensive on broad valuation measures even as recent results and oncology momentum have been mixed.
THE APEX TIMES
Pfizer’s stock closed lower on the day, but the move came in a session where other market indicators were trending better, underscoring how investors are still calibrating sentiment toward the healthcare sector.
THE APEX TIMES
A recent market commentary argues Pfizer could be mispriced by the market’s focus on first-wave GLP-1 leaders, suggesting “better later than never” if the company finds the right path into the fast-growing weight-loss and metabolic-drug category.
